Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation.
Akamatsu H, Ozawa Y, Oyanagi J, Fujimoto D, Hata A, Katakami N, Tomii K, Murakami E, Sugimoto T, Shimokawa T, Koh Y, Yamamoto N.
Akamatsu H, et al. Among authors: hata a.
Anticancer Res. 2021 Feb;41(2):911-917. doi: 10.21873/anticanres.14844.
Anticancer Res. 2021.
PMID: 33517297
Clinical Trial.